Dynavax to Report Additional Immunogenicity Data for HEPLISAV(TM) Phase 3 Trial
BERKELEY, CA, Sep 16, 2011 (MARKETWIRE via COMTEX) -- Dynavax Technologies
Corporation (DVAX) today announced that on Sunday, September 18, at 11:30 am CDT
at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy
(ICAAC), the company will present additional immunogenicity data from its Phase 3
trial (HBV-16) evaluating the immunogenicity and safety of HEPLISAV versus
Engerix-B(R). Tyler Martin, M.D., President and Chief Medical Officer of Dynavax,
will make an oral presentation in Session No. 80 "New Trends in Vaccines." The
location of the presentation (#G1-534) is Meeting Room W194a of the McCormick
Place convention center in Chicago, IL where the ICAAC annual meeting is taking
place.
About HEPLISAV
HEPLISAV is an investigational adult hepatitis B vaccine. In an earlier completed
pivotal Phase 3 trial, HEPLISAV demonstrated increased, rapid protection with
fewer doses than current licensed vaccines. Dynavax has worldwide commercial
rights to HEPLISAV and is developing the vaccine for large, high-value
populations that are less responsive to current licensed vaccines, including
individuals with chronic kidney disease. HEPLISAV combines hepatitis B surface
antigen with a proprietary Toll-like Receptor 9 agonist known as ISS to enhance
the immune response.
About Dynavax
Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company,
discovers and develops novel products to prevent and treat infectious and
inflammatory diseases. The Company's lead product candidate is HEPLISAV, a Phase
3 investigational adult hepatitis B vaccine designed to provide rapid and
superior protection with fewer doses than current licensed vaccines. For more
information visit dynavax.com.
Engerix-B(R) is a registered trademark of GlaxoSmithKline
Contact:
Michael Ostrach
Vice President and Chief Business Officer
510-665-7257
Email Contact |
